RecruitingPHASE1, PHASE2NCT06826612
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
Studying Huntington disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-LaRoche
- Intervention
- SPK-10001(genetic)
- Enrollment
- 53 enrolled
- Eligibility
- 25-65 years · All sexes
- Timeline
- 2025 – 2035
Study locations (5)
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburg, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06826612 on ClinicalTrials.govOther trials for Huntington disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07513844Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's DiseaseFirst Affiliated Hospital of Fujian Medical University
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07537075An Extension of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGPHASE3NCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07451613Safety and Tolerability Study of Human Neural Stem Cells for Huntington's DiseaseLeslie Thompson
- RECRUITINGEARLY PHASE1NCT06634628iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009CHDI Foundation, Inc.
- RECRUITINGPHASE2, PHASE3NCT07378644Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGNCT07253038Evaluation of Three Tests to Assess Social Cognition in Huntington DiseaseRegion Skane
- RECRUITINGNANCT07213648Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)University of Virginia